# Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

> **NCT05102071** · — · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Diabetes Mellitus, Type 2
- Cardiovascular Diseases

## Interventions

- **DRUG:** empagliflozin
- **DRUG:** metformin
- **DRUG:** sulfonylurea

## Key facts

- **NCT ID:** NCT05102071
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was canceled because database sample size was inadequate.
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102071, "Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05102071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*